Sunesis Pharmaceuticals (SNSS) Reports In-Line Q1 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Sunesis Pharmaceuticals (SNSS) Reports In-Line Q1 EPS

Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights

May 5, 2016 7:02 AM EDT

SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2016. Loss from operations for the three months ended March 31, 2016 was $10.1 million. As of March 31, 2016, cash, cash equivalents and marketable securities totaled $40.0 million.

The first quarter of 2016 saw several important milestones, including, notably, the advancement of our unique BTK-inhibitor SNS-062 into the clinic in a Phase 1A study, said Daniel Swisher, Chief Executive Officer of Sunesis. Resistance to available BTK-inhibitors is a growing concern, and SNS-062s... More